Effects of Prior Fluoxetine Treatment on ? Sleep in Women with Recurrent Depression

Buysse, Daniel J.; Kupfer, David J.; Cherry, Christine; Stapf, Deborah M.; Frank, Ellen

doi:10.1016/s0893-133x(99)00025-1

Cited by 13 publications

(9 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This increase might accompany treatment response. Earlier studies showed that the REM-density was increased in women treated with fluoxetine even after the drug was discontinued compared to a pre-drug condition (Buysse et al, 1999b), whereas, in contrast, depressed patients treated nonpharmacologically show a decrease in REM density in the course of treatment (Thase et al, 1994;Buysse et al, 1999b). This points to a complex interaction of different structures involved in REM-sleep regulation.…”

Section: Discussionmentioning

confidence: 99%

“…However, other studies show that early changes of REM sleep parameters, especially REM latency and percentage amount of REM during the sleep period time, might predict treatment outcome with substances, which have an accute effect on REM sleep like amitriptyline (Kupfer et al, 1981;Gillin et al, 1978) and clomipramine (Höchli et al, 1986). Furthermore, changes in REM sleep, especially REM density, occur in the course of antidepressive treatment with fluoxetine (Buysse et al, 1999a) leading to an increase in REM density, whereas under nonpharmacological treatment (Thase et al, 1994;Buysse et al, 1999a) REM density decreases. In drug-free depressed patients, an increased REM density is a state marker of depression (Lauer et al, 1991).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

State Markers of Depression in Sleep EEG: Dependency on Drug and Gender in Patients Treated with Tianeptine or Paroxetine

Murck

Nickel

Künzel

et al. 2003

Neuropsychopharmacol

View full text Add to dashboard Cite

Tianeptine enhances while paroxetine inhibits serotonin reuptake into neurons; however, both show an antidepressive action. A subgroup of 38 depressed patients from a drug trial comparing the efficacy of tianeptine with that of paroxetine was studied with regard to their effects on sleep regulation, especially in relation to treatment response. We recorded sleep EEGs at day 7 and day 42 after the start of treatment with either compound, which allows measurement of changes due to the antidepressive medication in relation to the duration of treatment. Spectral analysis of the non-REM sleep EEG revealed a strong decline in the higher sigma frequency range (14-16 Hz) in male treatment responders independent of medication, whereas nonresponders did not show marked changes in this frequency range independent of gender. The patients receiving paroxetine showed less REM sleep and more intermittent wakefulness compared to the patients receiving tianeptine. REM density after 1 week of treatment was a predictor of treatment response in the whole sample. Psychopathological features with regard to the score in single items of the HAMD revealed predictive markers for response, some of which were opposite in the gender groups, especially those related to somatic anxiety. Changes in REM density were inversely correlated to the changes in HAMD in the paroxetine, but not the tianeptine, group. Our data suggest the importance of taking gender into account in the study of the biological effects of drugs. The study further points to the importance of the higher sigma frequency range in the sleep EEG of non-REM sleep and REM density as a marker of treatment response.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

State Markers of Depression in Sleep EEG: Dependency on Drug and Gender in Patients Treated with Tianeptine or Paroxetine

Murck

Nickel

Künzel

et al. 2003

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Thus, REM latency changes may be associated with the mechanism of action of many antidepressants as previously suggested (Vogel 1983;Vogel et al 1975; this includes many SSRIs and specifically fluoxetine; cf. Buysse et al 1999;Trivedi et al 1999), but not of all antidepressants. Much less is known about delta ratio changes due to various antidepressants, allowing the speculation that the delta sleep ratio could be closer to a general mechanism of antidepressant action than REM latency.…”

mentioning

confidence: 92%

Fluoxetine and Sleep EEG Effects of a Single Dose, Subchronic Treatment, and Discontinuation in Healthy Subjects

Feige

2002

Neuropsychopharmacology

View full text Add to dashboard Cite

In the last years, selective serotonin reuptake inhibitors (SSRIs) have increasingly replaced tricyclics in antidepressive treatment due to their more benign side effect profile. Still, compliance in long-term maintenance therapy often enough is insufficient, since many patients are reluctant to accept daily dosing of antidepressants and thus tend to omit medication sometimes. It is well known for most antidepressants that a discontinu-

show abstract

“…However, those MDD patients who present with clinically significant insomnia complaints comprise a particularly challenging group to treat. For many such patients, insomnia represents a long-standing and problematic condition that can: (1) predate the onset of MDD, 6,7 (2) increase the risk of suicide, 8,9 (3) show a suboptimal response to traditional depression treatment, 10,11 (4) remain after successful depression treatment, 12,13 and (5) increase risk for MDD relapse (e.g., Nierenberg et al 14 ). Perhaps because the insomnia of MDD patients traditionally has been viewed as an MDD symptom rather than a comorbid disorder, the sleep-specific treatment needs of MDD patients have been largely ignored until recently.…”

Section: Introductionmentioning

confidence: 99%

Cognitive Behavioral Insomnia Therapy for Those With Insomnia and Depression: A Randomized Controlled Clinical Trial

Carney

Edinger

Kuchibhatla

et al. 2017

Sleep

153

View full text Add to dashboard Cite

Study Objective: To compare cognitive behavioral therapy for insomnia (CBT-I) + antidepressant medication (AD) against treatments that target solely depression or solely insomnia. Design: A blinded, randomized split-plot experimental study. Setting: Two urban academic clinical centers. Participants: 107 participants (68% female, mean age 42 ± 11) with major depressive disorder and insomnia. Interventions: Randomization was to one of three groups: antidepressant (AD; escitalopram) + CBT-I (4 sessions), CBT-I + placebo pill, or AD + 4-session sleep hygiene control (SH). Measurements and Results: Subjective sleep was assessed via 2 weeks of daily sleep diaries (use of medication was covaried in all analyses); although there were no statistically significant group differences detected, all groups improved from baseline to posttreatment on subjective sleep efficiency (SE) and total wake time (TWT) and the effect sizes were large. Objective sleep was assessed via overnight polysomnographic monitoring at baseline and posttreatment; analyses revealed both CBT groups improved on TWT (p = .03), but the AD + SH group worsened. There was no statistically significant effect for PSG SE (p = .07). There was a between groups medium effect observed for the AD + SH and CBT + placebo group differences on diary TWT and both PSG variables. All groups improved significantly from baseline to posttreatment on the Hamilton Rating Scale for Depression (HAMD-17); the groups did not differ. Conclusions: Although all groups self-reported sleeping better after treatment, only the CBT-I groups improved on objective sleep, and AD + SH's sleep worsened. This suggests that we should be treating sleep in those with depression with an effective insomnia treatment and relying on self-report obscures sleep worsening effects. All groups improved on depression, even a group with absolutely no depression-focused treatment component (CBT-I + placebo). The depression effect in CBT-I only group has been reported in other studies, suggesting that we should further investigate the antidepressant properties of CBT-I.

show abstract

Effects of Prior Fluoxetine Treatment on ? Sleep in Women with Recurrent Depression

Cited by 13 publications

References 50 publications

State Markers of Depression in Sleep EEG: Dependency on Drug and Gender in Patients Treated with Tianeptine or Paroxetine

State Markers of Depression in Sleep EEG: Dependency on Drug and Gender in Patients Treated with Tianeptine or Paroxetine

Fluoxetine and Sleep EEG Effects of a Single Dose, Subchronic Treatment, and Discontinuation in Healthy Subjects

Cognitive Behavioral Insomnia Therapy for Those With Insomnia and Depression: A Randomized Controlled Clinical Trial

Contact Info

Product

Resources

About